



Quarterly Newsletter: Winter 2025



A Year in Review: 2024


Phase Genomics continued to pioneer genomic innovation, driving advancements in human health and life science research over another impactful year. Join us in celebrating all the incredible milestones of 2024 and get a look at what's to come in our latest blog post. Wishing you a Happy New Year from the Phase Genomics team!

[READ HERE](#)

Upgraded Platforms and Data Analysis

Insights in Oncology

[Genomic Proximity Mapping™ \(GPM\)](#) is an upgraded approach to cytogenetic analysis – meeting and surpassing current risk stratification assessments. This year, our cytogenetic platform uncovered novel, clinically-relevant chromosomal aberrations critical for assessing patient care in oncology. Read more [here »](#)



Diving into the Data

Two new data analysis tools were made available to ProxiMeta and CytoTerra platform users this year: ProxiMeta™ Explorer and CytoTerra® Curator.

[ProxiMeta™ Explorer](#) is an interactive, cloud-based, genome-resolved metagenomic analysis platform for data visualization and exploration. The platform provides fully customizable analyses and reports for tracking genomes across time, conditions, groups, and more with a click of a button.


[CytoTerra® Curator](#) enables users to effortlessly review, revise, and generate reports from cytogenetic data – no prior bioinformatics experience required. From curating calls to constructing circos plots, Curator provides fast, accurate insights for human genomics and oncology research.

Research & Innovation Highlights 2023



Cow Burps & Super Bugs

We are actively developing solutions to address the growing threat of antimicrobial resistance and in the same stroke, advancing environmental health efforts with lysin discovery. Discover how we are turning the tables using our antimicrobial discovery platform [here »](#)



Microbiome Vaccines

Phase Genomics' metagenomic deconvolution technology helped crack the code on a potential new vaccine for farmed salmon to defend against sea lice by targeting the parasite's microbiome. Read the full article published in The Economist [here »](#)

Have a project in mind?

Contact Us

Phase Genomics, 1617 8th Ave N, Seattle, Washington 98109, United States, 833-742-7436

[Unsubscribe](#)

For research purposes only, not for clinical or diagnostic use.